(MEDP) Medpace Holdings - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US58506Q1094
Clinical Trials, Regulatory Services, Data Management, Laboratory Testing
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 43.2% |
| Value at Risk 5%th | 60.6% |
| Relative Tail Risk | -14.79% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.88 |
| Alpha | 45.20 |
| CAGR/Max DD | 0.93 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.505 |
| Beta | 0.979 |
| Beta Downside | 0.975 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.38% |
| Mean DD | 13.04% |
| Median DD | 8.71% |
Description: MEDP Medpace Holdings November 03, 2025
Medpace Holdings, Inc. (NASDAQ: MEDP) is a contract research organization that delivers end-to-end clinical development services-including trial design, central lab coordination, regulatory affairs, monitoring, data management, pharmacovigilance, and post-marketing support-to pharmaceutical, biotech, and medical-device clients across North America, Europe, and Asia. Its portfolio spans Phase I through Phase IV studies and encompasses ancillary capabilities such as bio-analytical labs, human pharmacology, imaging, and ECG read-outs.
Key recent metrics: FY 2023 revenue reached $1.06 billion, up ~7 % YoY, driven by higher enrollment volumes in oncology and rare-disease trials; the CRO industry is projected to grow at a CAGR of ~6 % through 2028, reflecting sustained biotech financing and accelerated drug pipelines; and Medpace’s operating margin improved to 12.5 % as it leveraged a “full-service” model to capture higher-value regulatory and data-analytics fees. A material driver of future performance is the U.S. FDA’s emphasis on real-world evidence, which could expand demand for Medpace’s post-marketing and pharmacovigilance services.
For a deeper, data-rich assessment of MEDP’s valuation relative to sector peers, you may find the analytics on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income (433.0m TTM) > 0 and > 6% of Revenue (6% = 141.5m TTM) |
| FCFTA 0.40 (>2.0%) and ΔFCFTA 14.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -23.18% (prev -0.42%; Δ -22.76pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.41 (>3.0%) and CFO 711.2m > Net Income 433.0m (YES >=105%, WARN >=100%) |
| Net Debt (-141.4m) to EBITDA (520.8m) ratio: -0.27 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (29.7m) change vs 12m ago -7.41% (target <= -2.0% for YES) |
| Gross Margin 31.11% (prev 29.69%; Δ 1.42pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 122.9% (prev 99.37%; Δ 23.56pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 64.22 (EBITDA TTM 520.8m / Interest Expense TTM 7.88m) >= 6 (WARN >= 3) |
Altman Z'' -1.81
| (A) -0.31 = (Total Current Assets 737.3m - Total Current Liabilities 1.28b) / Total Assets 1.75b |
| (B) -0.34 = Retained Earnings (Balance) -596.2m / Total Assets 1.75b |
| (C) 0.26 = EBIT TTM 506.3m / Avg Total Assets 1.92b |
| (D) -0.41 = Book Value of Equity -601.6m / Total Liabilities 1.46b |
| Total Rating: -1.81 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 95.22
| 1. Piotroski 9.0pt |
| 2. FCF Yield 4.15% |
| 3. FCF Margin 29.83% |
| 4. Debt/Equity 0.49 |
| 5. Debt/Ebitda -0.27 |
| 6. ROIC - WACC (= 74.01)% |
| 7. RoE 91.88% |
| 8. Rev. Trend 97.50% |
| 9. EPS Trend 89.88% |
What is the price of MEDP shares?
As of December 10, 2025, the stock is trading at USD 544.08 with a total of 210,303 shares traded.
Over the past week, the price has changed by -6.79%, over one month by -9.39%, over three months by +12.05% and over the past year by +54.47%.
Over the past week, the price has changed by -6.79%, over one month by -9.39%, over three months by +12.05% and over the past year by +54.47%.
Is MEDP a buy, sell or hold?
Medpace Holdings has received a consensus analysts rating of 3.33.
Therefor, it is recommend to hold MEDP.
- Strong Buy: 2
- Buy: 0
- Hold: 10
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MEDP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 538.3 | -1.1% |
| Analysts Target Price | 538.3 | -1.1% |
| ValueRay Target Price | 719.5 | 32.2% |
MEDP Fundamental Data Overview November 29, 2025
Market Cap USD = 17.09b (17.09b USD * 1.0 USD.USD)
P/E Trailing = 42.3603
P/E Forward = 38.0228
P/S = 7.2452
P/B = 58.1896
P/EG = 3.8476
Beta = 1.43
Revenue TTM = 2.36b USD
EBIT TTM = 506.3m USD
EBITDA TTM = 520.8m USD
Long Term Debt = 119.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 24.9m USD (from shortTermDebt, last quarter)
Debt = 144.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -141.4m USD (from netDebt column, last quarter)
Enterprise Value = 16.95b USD (17.09b + Debt 144.0m - CCE 285.4m)
Interest Coverage Ratio = 64.22 (Ebit TTM 506.3m / Interest Expense TTM 7.88m)
FCF Yield = 4.15% (FCF TTM 703.6m / Enterprise Value 16.95b)
FCF Margin = 29.83% (FCF TTM 703.6m / Revenue TTM 2.36b)
Net Margin = 18.36% (Net Income TTM 433.0m / Revenue TTM 2.36b)
Gross Margin = 31.11% ((Revenue TTM 2.36b - Cost of Revenue TTM 1.62b) / Revenue TTM)
Gross Margin QoQ = 29.84% (prev 29.84%)
Tobins Q-Ratio = 9.67 (Enterprise Value 16.95b / Total Assets 1.75b)
Interest Expense / Debt = 5.48% (Interest Expense 7.88m / Debt 144.0m)
Taxrate = 22.19% (31.7m / 142.8m)
NOPAT = 393.9m (EBIT 506.3m * (1 - 22.19%))
Current Ratio = 0.57 (Total Current Assets 737.3m / Total Current Liabilities 1.28b)
Debt / Equity = 0.49 (Debt 144.0m / totalStockholderEquity, last quarter 293.6m)
Debt / EBITDA = -0.27 (Net Debt -141.4m / EBITDA 520.8m)
Debt / FCF = -0.20 (Net Debt -141.4m / FCF TTM 703.6m)
Total Stockholder Equity = 471.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 24.70% (Net Income 433.0m / Total Assets 1.75b)
RoE = 91.88% (Net Income TTM 433.0m / Total Stockholder Equity 471.3m)
RoCE = 85.76% (EBIT 506.3m / Capital Employed (Equity 471.3m + L.T.Debt 119.1m))
RoIC = 83.58% (NOPAT 393.9m / Invested Capital 471.3m)
WACC = 9.58% (E(17.09b)/V(17.23b) * Re(9.62%) + D(144.0m)/V(17.23b) * Rd(5.48%) * (1-Tc(0.22)))
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -3.38%
[DCF Debug] Terminal Value 76.49% ; FCFE base≈636.4m ; Y1≈785.1m ; Y5≈1.34b
Fair Price DCF = 611.1 (DCF Value 17.21b / Shares Outstanding 28.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 89.88 | EPS CAGR: 33.13% | SUE: 1.41 | # QB: 1
Revenue Correlation: 97.50 | Revenue CAGR: 22.47% | SUE: 0.77 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.38 | Chg30d=-0.266 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=16.49 | Chg30d=+0.908 | Revisions Net=+7 | Growth EPS=+9.0% | Growth Revenue=+12.0%
P/E Trailing = 42.3603
P/E Forward = 38.0228
P/S = 7.2452
P/B = 58.1896
P/EG = 3.8476
Beta = 1.43
Revenue TTM = 2.36b USD
EBIT TTM = 506.3m USD
EBITDA TTM = 520.8m USD
Long Term Debt = 119.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 24.9m USD (from shortTermDebt, last quarter)
Debt = 144.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -141.4m USD (from netDebt column, last quarter)
Enterprise Value = 16.95b USD (17.09b + Debt 144.0m - CCE 285.4m)
Interest Coverage Ratio = 64.22 (Ebit TTM 506.3m / Interest Expense TTM 7.88m)
FCF Yield = 4.15% (FCF TTM 703.6m / Enterprise Value 16.95b)
FCF Margin = 29.83% (FCF TTM 703.6m / Revenue TTM 2.36b)
Net Margin = 18.36% (Net Income TTM 433.0m / Revenue TTM 2.36b)
Gross Margin = 31.11% ((Revenue TTM 2.36b - Cost of Revenue TTM 1.62b) / Revenue TTM)
Gross Margin QoQ = 29.84% (prev 29.84%)
Tobins Q-Ratio = 9.67 (Enterprise Value 16.95b / Total Assets 1.75b)
Interest Expense / Debt = 5.48% (Interest Expense 7.88m / Debt 144.0m)
Taxrate = 22.19% (31.7m / 142.8m)
NOPAT = 393.9m (EBIT 506.3m * (1 - 22.19%))
Current Ratio = 0.57 (Total Current Assets 737.3m / Total Current Liabilities 1.28b)
Debt / Equity = 0.49 (Debt 144.0m / totalStockholderEquity, last quarter 293.6m)
Debt / EBITDA = -0.27 (Net Debt -141.4m / EBITDA 520.8m)
Debt / FCF = -0.20 (Net Debt -141.4m / FCF TTM 703.6m)
Total Stockholder Equity = 471.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 24.70% (Net Income 433.0m / Total Assets 1.75b)
RoE = 91.88% (Net Income TTM 433.0m / Total Stockholder Equity 471.3m)
RoCE = 85.76% (EBIT 506.3m / Capital Employed (Equity 471.3m + L.T.Debt 119.1m))
RoIC = 83.58% (NOPAT 393.9m / Invested Capital 471.3m)
WACC = 9.58% (E(17.09b)/V(17.23b) * Re(9.62%) + D(144.0m)/V(17.23b) * Rd(5.48%) * (1-Tc(0.22)))
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -3.38%
[DCF Debug] Terminal Value 76.49% ; FCFE base≈636.4m ; Y1≈785.1m ; Y5≈1.34b
Fair Price DCF = 611.1 (DCF Value 17.21b / Shares Outstanding 28.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 89.88 | EPS CAGR: 33.13% | SUE: 1.41 | # QB: 1
Revenue Correlation: 97.50 | Revenue CAGR: 22.47% | SUE: 0.77 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.38 | Chg30d=-0.266 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=16.49 | Chg30d=+0.908 | Revisions Net=+7 | Growth EPS=+9.0% | Growth Revenue=+12.0%
Additional Sources for MEDP Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle